AI watchdog for cancer radiation: could it prevent costly mistakes?
NCT ID NCT07463833
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an artificial intelligence (AI) tool designed to help doctors and physicists review radiation treatment plans for cancer patients before therapy begins. The AI highlights differences in how providers plan treatments and flags potential warning signs, aiming to reduce errors and improve safety. About 207 participants (providers and prostate cancer patients) will take part, with the AI embedded in routine peer-review meetings.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Artificial intelligence (AI) decision-support software
What this could lead to
If successful, this AI tool could help doctors and physicists catch more mistakes in radiation treatment plans, making cancer therapy safer for patients.
What could go wrong
This is an early-stage study focused on process improvement, not a direct treatment. The AI may not reduce errors significantly or could add complexity without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina at Chapel Hill, Department of Radiation Oncology
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••